Related Experiment Video
Updated: Jul 12, 2025

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
Clinically isolated syndrome: Diagnosis and risk of developing clinically definite multiple sclerosis
J López-Gómez1, B Sacristán Enciso2, M A Caro Miró3
1Unidad de Proteínas, Servicio de Análisis Clínicos, Hospital Universitario de Badajoz, Badajoz, Spain.
Introduction:
In most cases, multiple sclerosis (MS) initially presents as clinically isolated syndrome (CIS). Differentiating CIS from other acute or subacute neurological diseases and estimating the risk of progression to clinically definite MS is essential since presenting a second episode in a short time is associated with poorer long-term prognosis.
Development:
We conducted a literature review to evaluate the usefulness of different variables in improving diagnostic accuracy and predicting progression from CIS to MS, including magnetic resonance imaging (MRI) and such biofluid markers as oligoclonal IgG and IgM bands, lipid-specific oligoclonal IgM bands in the CSF, CSF kappa free light-chain (KFLC) index, neurofilament light chain (NfL) in the CSF and serum, and chitinase 3-like protein 1 (CHI3L1) in the CSF and serum.
Conclusions:
Codetection of oligoclonal IgG bands and MRI lesions reduces diagnostic delays and suggests a high risk of CIS progression to MS. A KFLC index > 10.6 and CSF NfL concentrations > 1150 ng/L indicate that CIS is more likely to progress to MS within one year (40%-50%); 90% of patients with CIS and serum CHI3L1 levels > 33 ng/mL and 100% of those with lipid-specific oligoclonal IgM bands present MS within one year of CIS onset.
Insights
Diagnosing clinically isolated syndrome (CIS) and predicting multiple sclerosis (MS) progression is crucial. Combining MRI and oligoclonal IgG bands aids early MS diagnosis and risk assessment.
Area of Science:
- Neurology
- Neuroimmunology
- Biomarker Discovery
Background:
- Multiple sclerosis (MS) often begins as clinically isolated syndrome (CIS).
- Accurate CIS diagnosis and prognosis are vital for patient outcomes, as early progression is linked to poorer long-term prognosis.
Purpose of the Study:
- To review diagnostic variables for improving accuracy in CIS.
- To evaluate predictors of CIS progression to clinically definite MS.
Main Methods:
- Literature review assessing magnetic resonance imaging (MRI) utility.
- Evaluation of biofluid markers: oligoclonal IgG/IgM bands, CSF kappa free light-chain (KFLC) index, CSF/serum neurofilament light chain (NfL), and CSF/serum chitinase 3-like protein 1 (CHI3L1).
Main Results:
- Codetection of oligoclonal IgG bands and MRI lesions shortens diagnostic time and indicates high MS progression risk.
- Specific thresholds for KFLC index (>10.6) and CSF NfL (>1150 ng/L) predict 40-50% one-year MS progression.
- Elevated serum CHI3L1 (>33 ng/mL) or presence of lipid-specific oligoclonal IgM bands predict MS onset within one year in 90-100% of CIS patients.
Conclusions:
- Combined MRI and oligoclonal IgG band detection improves CIS diagnosis and identifies high-risk patients.
- Specific biomarkers like KFLC index, NfL, CHI3L1, and lipid-specific IgM bands offer valuable prognostic information for CIS progression to MS.
More Related Videos
Related Concept Videos
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Acute Coronary Syndrome III: Diagnostic Studies
Myocarditis II: Clinical Features and Diagnostic Tests

